FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2772893103> ?p ?o ?g. }

• W2772893103 endingPage "e018748" @default.
• W2772893103 startingPage "e018748" @default.
• W2772893103 abstract "Introduction Antineutrophil cytoplasm antibody-associated vasculitis (AAV) is a form of systemic vasculitis. The current standard induction therapy with the combination of high-dose glucocorticoids and cyclophosphamide or rituximab has high remission rates of 80%–90%. However, it is also associated with various side effects, including death due to infection or cardiovascular disease. There is an unmet medical need of a new therapy to reduce side effects. Methods and analysis This is a phase IV multicentre, open-label, randomised controlled trial that aims to evaluate the efficacy and safety of a new remission induction regimen with the combination of low-dose glucocorticoids and rituximab. Newly diagnosed patients with AAV will be assessed for eligibility at 34 tertiary rheumatology/nephrology centres in Japan. One hundred and forty patients will be randomised (1:1) to receive low-dose prednisolone (0.5 mg/kg daily) plus rituximab (375 mg/m 2 weekly) or high-dose prednisolone (1 mg/kg daily) plus rituximab. The trial consists of remission induction and maintenance phases. The primary endpoint of the study is the remission rate at 6 months (induction phase). Relapse and long-term safety profile will also be assessed until 24 months (maintenance phase). Ethics and dissemination The protocol was first approved by the Institutional Review Board of Chiba University Hospital (reference number: G25051), and then approved by each participating site. The trial was registered at the University hospital Medical Information Network (UMIN) clinical registry (UMIN000014222) and ClinicalTrials.gov registry ( NCT02198248 ). The Low-dose Glucocorticoid Vasculitis Induction Study (LoVAS) trial is currently ongoing and is due to finish in September 2019. The findings of this trial will be disseminated to participants through peer-reviewed publications and presented at national and international conferences in accordance with the Consolidated Standards of Reporting Trials (CONSORT) Statement. Trial registration number UMIN000014222; NCT02198248 ." @default.
• W2772893103 created "2017-12-22" @default.
• W2772893103 creator A5012506063 @default.
• W2772893103 creator A5025120343 @default.
• W2772893103 creator A5036684201 @default.
• W2772893103 creator A5039165431 @default.
• W2772893103 creator A5056778401 @default.
• W2772893103 creator A5061499769 @default.
• W2772893103 creator A5061671142 @default.
• W2772893103 creator A5061929521 @default.
• W2772893103 creator A5065724424 @default.
• W2772893103 creator A5072897343 @default.
• W2772893103 creator A5075995650 @default.
• W2772893103 creator A5087307078 @default.
• W2772893103 date "2017-12-01" @default.
• W2772893103 modified "2023-09-26" @default.
• W2772893103 title "Low-dose glucocorticoids plus rituximab versus high-dose glucocorticoids plus rituximab for remission induction in ANCA-associated vasculitis (LoVAS): protocol for a multicentre, open-label, randomised controlled trial" @default.
• W2772893103 cites W1914343637 @default.
• W2772893103 cites W1968137793 @default.
• W2772893103 cites W1977891218 @default.
• W2772893103 cites W1989782403 @default.
• W2772893103 cites W2000366267 @default.
• W2772893103 cites W2029724069 @default.
• W2772893103 cites W2031517139 @default.
• W2772893103 cites W2042591605 @default.
• W2772893103 cites W2058357963 @default.
• W2772893103 cites W2063340779 @default.
• W2772893103 cites W2071333258 @default.
• W2772893103 cites W2071782320 @default.
• W2772893103 cites W2084056567 @default.
• W2772893103 cites W2098974730 @default.
• W2772893103 cites W2100809783 @default.
• W2772893103 cites W2109207289 @default.
• W2772893103 cites W2120427700 @default.
• W2772893103 cites W2124208349 @default.
• W2772893103 cites W2126694261 @default.
• W2772893103 cites W2126960177 @default.
• W2772893103 cites W2131153587 @default.
• W2772893103 cites W2131235777 @default.
• W2772893103 cites W2141225393 @default.
• W2772893103 cites W2147350349 @default.
• W2772893103 cites W2151319492 @default.
• W2772893103 cites W2165454325 @default.
• W2772893103 cites W2474029657 @default.
• W2772893103 cites W4230947289 @default.
• W2772893103 doi "https://doi.org/10.1136/bmjopen-2017-018748" @default.
• W2772893103 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5778278" @default.
• W2772893103 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29247107" @default.
• W2772893103 hasPublicationYear "2017" @default.
• W2772893103 type Work @default.
• W2772893103 sameAs 2772893103 @default.
• W2772893103 citedByCount "14" @default.
• W2772893103 countsByYear W27728931032018 @default.
• W2772893103 countsByYear W27728931032019 @default.
• W2772893103 countsByYear W27728931032020 @default.
• W2772893103 countsByYear W27728931032021 @default.
• W2772893103 crossrefType "journal-article" @default.
• W2772893103 hasAuthorship W2772893103A5012506063 @default.
• W2772893103 hasAuthorship W2772893103A5025120343 @default.
• W2772893103 hasAuthorship W2772893103A5036684201 @default.
• W2772893103 hasAuthorship W2772893103A5039165431 @default.
• W2772893103 hasAuthorship W2772893103A5056778401 @default.
• W2772893103 hasAuthorship W2772893103A5061499769 @default.
• W2772893103 hasAuthorship W2772893103A5061671142 @default.
• W2772893103 hasAuthorship W2772893103A5061929521 @default.
• W2772893103 hasAuthorship W2772893103A5065724424 @default.
• W2772893103 hasAuthorship W2772893103A5072897343 @default.
• W2772893103 hasAuthorship W2772893103A5075995650 @default.
• W2772893103 hasAuthorship W2772893103A5087307078 @default.
• W2772893103 hasBestOaLocation W27728931031 @default.
• W2772893103 hasConcept C126322002 @default.
• W2772893103 hasConcept C141071460 @default.
• W2772893103 hasConcept C168563851 @default.
• W2772893103 hasConcept C198451711 @default.
• W2772893103 hasConcept C203092338 @default.
• W2772893103 hasConcept C2776015282 @default.
• W2772893103 hasConcept C2776715498 @default.
• W2772893103 hasConcept C2778720950 @default.
• W2772893103 hasConcept C2779134260 @default.
• W2772893103 hasConcept C2779338263 @default.
• W2772893103 hasConcept C2780653079 @default.
• W2772893103 hasConcept C2781413609 @default.
• W2772893103 hasConcept C535046627 @default.
• W2772893103 hasConcept C71924100 @default.
• W2772893103 hasConceptScore W2772893103C126322002 @default.
• W2772893103 hasConceptScore W2772893103C141071460 @default.
• W2772893103 hasConceptScore W2772893103C168563851 @default.
• W2772893103 hasConceptScore W2772893103C198451711 @default.
• W2772893103 hasConceptScore W2772893103C203092338 @default.
• W2772893103 hasConceptScore W2772893103C2776015282 @default.
• W2772893103 hasConceptScore W2772893103C2776715498 @default.
• W2772893103 hasConceptScore W2772893103C2778720950 @default.
• W2772893103 hasConceptScore W2772893103C2779134260 @default.
• W2772893103 hasConceptScore W2772893103C2779338263 @default.
• W2772893103 hasConceptScore W2772893103C2780653079 @default.
• W2772893103 hasConceptScore W2772893103C2781413609 @default.
• W2772893103 hasConceptScore W2772893103C535046627 @default.
• W2772893103 hasConceptScore W2772893103C71924100 @default.

• next